SILVER SPRING, Md. (Nov. 19, 2025) Martha Sedegah, director of Naval Medical Research Command’s (NMRC) Clinical Immunology and Parasitology, Agile Vaccines and Therapeutics Department, poses for a photo in the Agile Vaccines and Therapeutics (AVAT) laboratory. She is the principal investigator working with other researchers to develop a nanoparticle vaccine model to provide a line of defense against malaria and other infectious diseases that include Lassa fever, SARS-CoV-2 and influenza. NMRC, headquarters of Navy Medicine Research & Development, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. (U.S. Navy photo by Tommy Lamkin/Released)
| Date Taken: | 11.19.2025 |
| Date Posted: | 11.20.2025 13:46 |
| Photo ID: | 9400494 |
| VIRIN: | 251119-N-UM734-1046 |
| Resolution: | 6095x4063 |
| Size: | 1.81 MB |
| Location: | SILVER SPRING, MARYLAND, US |
| Web Views: | 8 |
| Downloads: | 0 |
This work, NMRC Researchers Submit Provisional Patent for Nanoparticle Vaccine [Image 7 of 7], by Tommy Lamkin, identified by DVIDS, must comply with the restrictions shown on https://www.dvidshub.net/about/copyright.
NMRC Researchers Submit Provisional Patent for Nanoparticle Vaccine
No keywords found.
